PALISADE BIO, INC.: RA CAPITAL MANAGEMENT, L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
RA Capital Management, L.P. amended its Schedule 13G filing for Palisade Bio, Inc. under SEC accession 0001346824-26-000291. The amendment updates the firm's previously reported beneficial ownership position in the biotech company. Specific share counts and percentage figures were not disclosed in the filing headline. The move matters because 13G amendments signal shifts in major institutional holdings that can influence Palisade Bio's shareholder base and governance dynamics. Investors will watch for the detailed ownership figures in the full filing and any subsequent changes in RA Capital's position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Palisade Bio, Inc., RA Capital Management, L.P.